×
Home Companies Industry Politics Money Opinion LoungeMultimedia Science Education Sports TechnologyConsumerSpecialsMint on Sunday
×

Angel Broking puts SELL on Ranbaxy

Angel Broking puts SELL on Ranbaxy
Comment E-mail Print Share
First Published: Tue, Aug 25 2009. 10 45 AM IST
Updated: Tue, Aug 25 2009. 10 45 AM IST
Ranbaxy Laboratories has received the final approval from the US FDA to make and sell the generic version of Sciele Pharma’s peptic ulcer tablet Robinul for 1 mg and 2 mg dosages.
The company said that it plans to launch the drug in 4QCY2009. The annual market sales of Robinul are worth $26 million in the US.
The stock is up 39% in the past three months to Rs312, and is currently trading at 2.3x CY2010E earnings. We recommend a SELL rating on the stock, with a target price of Rs250.
Comment E-mail Print Share
First Published: Tue, Aug 25 2009. 10 45 AM IST
More Topics: Stock Ideas | Money Matters | Equities |